369 related articles for article (PubMed ID: 21467028)
21. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
Hayashi M; Tsutamoto T; Wada A; Tsutsui T; Ishii C; Ohno K; Fujii M; Taniguchi A; Hamatani T; Nozato Y; Kataoka K; Morigami N; Ohnishi M; Kinoshita M; Horie M
Circulation; 2003 May; 107(20):2559-65. PubMed ID: 12732605
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).
Gheorghiade M; Albaghdadi M; Zannad F; Fonarow GC; Böhm M; Gimpelewicz C; Botha J; Moores S; Lewis EF; Rattunde H; Maggioni A;
Eur J Heart Fail; 2011 Jan; 13(1):100-6. PubMed ID: 21123186
[TBL] [Abstract][Full Text] [Related]
24. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
25. Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Sanders-van Wijk S; Muzzarelli S; Neuhaus M; Kiencke S; Maeder M; Estlinbaum W; Tobler D; Mayer K; Erne P; Pfisterer ME; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Aug; 15(8):910-8. PubMed ID: 23666681
[TBL] [Abstract][Full Text] [Related]
26. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of microalbuminuria in chronic heart failure patients.
van de Wal RM; Asselbergs FW; Plokker HW; Smilde TD; Lok D; van Veldhuisen DJ; van Gilst WH; Voors AA
J Card Fail; 2005 Oct; 11(8):602-6. PubMed ID: 16230263
[TBL] [Abstract][Full Text] [Related]
28. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Hans-Henrik P
J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):118-21. PubMed ID: 21824990
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of plasma renin activity in heart failure.
Vergaro G; Emdin M; Iervasi A; Zyw L; Gabutti A; Poletti R; Mammini C; Giannoni A; Fontana M; Passino C
Am J Cardiol; 2011 Jul; 108(2):246-51. PubMed ID: 21545993
[TBL] [Abstract][Full Text] [Related]
30. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
31. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.
Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A
Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712
[TBL] [Abstract][Full Text] [Related]
32. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Persson F; Desai AS; Nicolaides M; Richard A; Xiang Z; Brunel P; Pfeffer MA;
N Engl J Med; 2012 Dec; 367(23):2204-13. PubMed ID: 23121378
[TBL] [Abstract][Full Text] [Related]
33. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension.
Strasser RH; Puig JG; Farsang C; Croket M; Li J; van Ingen H
J Hum Hypertens; 2007 Oct; 21(10):780-7. PubMed ID: 17541390
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
35. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
van Veldhuisen DJ; Cohen-Solal A; Böhm M; Anker SD; Babalis D; Roughton M; Coats AJ; Poole-Wilson PA; Flather MD;
J Am Coll Cardiol; 2009 Jun; 53(23):2150-8. PubMed ID: 19497441
[TBL] [Abstract][Full Text] [Related]
36. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
[TBL] [Abstract][Full Text] [Related]
37. Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Kushiro T; Itakura H; Abo Y; Gotou H; Terao S; Keefe DL
Hypertens Res; 2009 Mar; 32(3):169-75. PubMed ID: 19262478
[TBL] [Abstract][Full Text] [Related]
38. Aliskiren and perindopril reduce the levels of transforming growth factor-β in patients with non-diabetic kidney disease.
Lizakowski S; Tylicki L; Renke M; Rutkowski P; Heleniak Z; Sławińska-Morawska M; Aleksandrowicz-Wrona E; Małgorzewicz S; Rutkowski B
Am J Hypertens; 2012 Jun; 25(6):636-9. PubMed ID: 22357413
[TBL] [Abstract][Full Text] [Related]
39. Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Andersen K; Weinberger MH; Egan B; Constance CM; Wright M; Lukashevich V; Keefe DL
Cardiovasc Ther; 2010 Dec; 28(6):344-9. PubMed ID: 20406241
[TBL] [Abstract][Full Text] [Related]
40. Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context.
Krum H; Maggioni A
Clin Cardiol; 2010 Sep; 33(9):536-41. PubMed ID: 20842736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
